Bryan Oronsky

Bryan Oronsky

Company: EpicentRx

Job title: Chief Development Officer


RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases 11:30 am

Evaluate strategy and execution of drug design and translational development Understanding relevant pathology of disease and most up to date learnings on the inflammasome mechanisms, drug design, and patient population Exploring the latest data, potential biomarkers, challenges, and future directionsRead more

day: Day 1 - Track B - Morning

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.